Tower Semiconductor Rallied Over AI Push This Week
A wave of enthusiasm for AI infrastructure helped Tower Semiconductor leap higher this week. Investors spotlighted si...
What Budget Mistakes Can Ruin Your Savings
Budget missteps can erode savings fast. This introduction highlights key mistakes and simple fixes to safeguard your funds.
27,863 articles
Nervous About Spending? Stocks in Three Tech Giants
The AI spending spree has some investors on edge. This guide explains why three big tech leaders may weather the stor...
The $200,000 Down-Payment Dilemma: Gift Now or Wait
Rising housing costs and high rates push families to choose between gifting a large down payment now or waiting for a...
Why Age 63 Is the Most Expensive Year to Touch Your IRA
A large IRA move at 63 can trigger higher Medicare premiums for years, thanks to a two year income lookback. Near ret...
Amazon Alphabet's Custom Chips: Threat to Nvidia
As custom AI chips gain traction, investors wonder if amazon alphabet's custom chips can rival Nvidia. This article b...
T-Bills More Than Salary Stirs Retirement Plans
A growing number of seniors report t-bills more than salary as short-term yields rise, complicating the Social Securi...
Lilly Stock Heading $1,000? What Investors Should Know
Investors are watching Eli Lilly as GLP-1 drugs like Mounjaro and Zepbound power growth. This article breaks down the...
What Happening with Quantumscape Stock: Investor Update
Investors are buzzing about what happening with quantumscape. This article breaks down the core catalysts, risks, and...
Fund Cuts Helix Million: Is This $8 Energy Sleeper?
A prominent fund reduced its Helix Energy Solutions stake by roughly 4 million in the latest reporting period. As HLX...
PLBY (PLBY) 2026 Earnings: Deep Dive and Outlook Today
Investors are watching PLBY closely as plby (plby) 2026 earnings unfold. This article breaks down Q1 results, evaluat...
CoreWeave Fallen From 52-Week High: Bargain or Value Trap
CoreWeave has dropped substantially from its 52-week peak, leaving investors debating whether the bounce is coming or...
Forget Ozempic: This Obesity-Drug Giant Grabs GLP-1 Gold
As GLP-1 obesity therapies surge, one company is capturing the lion’s share of prescriptions and profits. This in-dep...
Popular Topics
Fable
Smart Money Moves For Everyday Life
Investment Strategies In Energy Sector
Best Index Funds For Retirement
Investment Strategies
Untitled D6eff7ea
Crypto For Beginners
Best Dividend Etfs
Index
Innovative Skincare Clinical
Dutch Salary
Blue Owl
Budget
Ai Healthcare News
Penalty Vs No Penalty Depending On Lock Status